New agents to treat life-threatening fungal infections

Current Topics in Medicinal Chemistry

Volumn 8, Issue 7, 2008, Pages 592-602

  Ting, Pauline C ^a   Walker, Scott S ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 [4 (4 CYANOPHENYL) 2 THIAZOLYL] 2 (2,5 DIFLUOROPHENYL) 2 HYDROXYBUTYL] 4 [1 [N METHYL N [3 [2 (METHYLAMINO)ACETOXYMETHYL] 2 PYRIDINYL]CARBAMOYLOXY]ETHYL] 1H 1,2,4 TRIAZOL 4 IUM CHLORIDE; 4 [2 [2 (2,5 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 4 THIAZOLYL]BENZONITRILE; 4 [4 [5 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4, TRIAZOL 1 YL)PROPYLTHIO] 1,3 DIOXAN 2 YL] 1,3 BUTADIENYL] 3 FLUOROBENZONITIRLE; ALBACONAZOLE; AMINOCANDIN; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CASPOFUNGIN; CHALCONE DERIVATIVE; COTRIMOXAZOLE; EMBECONAZOLE; FLUCONAZOLE; FLUCYTOSINE; GUANIDINE; HMR 3270; IMMUNOSUPPRESSIVE AGENT; IP 960; ITRACONAZOLE; MALEIMIDE; MICAFUNGIN; MICONAZOLE; PENTAMIDINE; POSACONAZOLE; PYRIDAZINONE DERIVATIVE; RAVUCONAZOLE; SORDARIN; SPK 843; UNINDEXED DRUG; VORICONAZOLE;

AREA UNDER THE CURVE; ASPERGILLOSIS; CANDIDIASIS; CHILL; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DYSPNEA; FLUSHING; FUNGAL STRAIN; HUMAN; HYPOKALEMIA; HYPOTENSION; INFECTION RISK; LOADING DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NAUSEA; NEPHROTOXICITY; NONHUMAN; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; VOMITING; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; FUNGUS;

ANTIFUNGAL AGENTS; DRUG DESIGN; FUNGI; HUMANS; MOLECULAR STRUCTURE; MYCOSES;

EID: 44949150199     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802608783955610     Document Type: Review

References (73)

1. McNeil, M. M.; Nash, S. L.; Hajjeh, R. A.; Phelan, M. A.; Conn, L. A.; Plikaytis, B. D.; Warnock, D. W. Trends in Mortality Due to Invasive Mycotic Diseases in the United States, 1980-1997. Clin. Infect. Dis. 2001, 33, 641-647.
2. Kauffman, C. A. Fungal Infections. Proc. Am. Thorac. Soc. 2006, 3, 35-40.
3. Enoch, D. A.; Ludlam, H. A.; Brown, N. M. Invasive fungal infections: A review of epidemiology and management options. J. Med. Micro. 2006, 55, 809-818.
4. Richardson, M. D. Changing patterns and trends in systemic fungal infections. J. Anitmicrob. Chemother. 2005, 56 suppl. S1, i5-i11.
5. Maschmeyer, G. The changing epidemiology of invasive fungal infections: new threats. Int. J. Antimicrob. Agents 2006, 27S, S3-S6.
6. Kibbler, C. C.; Seaton, S.; Barnes, R. A.; Gransden, W. R.; Holliman, R. E.; Johnson, E. M.; Perry, J. D.; Sullivan, D. J.; Wilson, J. A. Management and outcome of bloodstream infections due to Candida species in England: Wales. J. Hosp. Infect. 2003, 54, 18-24.
7. Clark, T. A.; Hajjeh, R. A. Recent trends in the epidemiology of invasive mycoses. Curr. Opin. Infect. Dis. 2002, 15, 569-574.
8. Odds, F. C.; Brown, A. J. P.; Gow, N. A. R. Antifungal Agents: mechanisms of action. Trends Microbiol. 2003, 11, 272-279.
9. Cuenca-Estrella, M.; Gómez-López, A.; Mellado, E.; Buitrago, M. J.; Monzón, A.; Rodríguez-Tudela, J. L. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob. Agents Chemother. 2006, 50, 917-921.
10. Dodds Ashley, F. S. Treatment options for invasive fungal infections. Pharmacotherapy 2006, 26, 55S-60S.
11. Loeffler, J.; Stevens, D. A. Antifungal drug resistance. Clin. Inf. Dis. 2003, 36 (Suppl. 1), S31-S41.
12. Aperis, G.; Mylonakis, E. Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opin. Investig. Drugs 2006, 15, 579-602.
13. Turner, M. S.; Drew, R. H.; Perfect, J. R. Emerging echinocandins for treatment of invasive fungal infections. Expert Opin. Emerg. Drugs 2006, 11, 231-250.
14. Ruge, E.; Korting, H. C.; Borelli, C. Current state of three-dimensional characterization of antifungal targets and its use for molecular modeling in drug design. Int. J. Antimicrob. Agents 2005, 26, 427-441.
15. Sugimoto, Y.; Sakoh, H.; Yamada, Y, IPC synthase as a useful target for antifungal drugs. Curr. Drug Targets Infect. Disord. 2004, 4, 311-322.
16. Gupta, P.; Singh, K.; Srinivasan, T.; Kundu, B. Identification of antifungal agents using combinatorial approach: An overview. Curr. Med. Chem. Anti-Infective Agents 2003, 2, 113-133.
17. Behr, J. B. Chitin synthase as an antifungal target recent advances. Curr. Med. Chem. Anti-Infective Agents 2003, 2, 173-189.
18. Niwano, Y.; Ohmi, T.; Seo, A.; Kodama, H.; Koga, H.; Sakai, A. Lanoconazole and its related optically active compound NND-502: Novel antifungal imidazoles with a ketene dithioacetal structure. Curr. Med. Chem. Anti-Infective Agents 2003, 2, 147-160.
19. Zotchev, S. B. Polyene macrolide antibiotics and their applications in human therapy. Curr. Med. Chem. Anti-Infective Agents 2003, 10, 211-223.
20. Sabatelli, F.; Patel, R.; Mann, P. A.; Mendrick, C. A.; Norris, C. C.; Hare, R.; Loebenberg, D.; Black, T. A.; McNicholas P. M. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother. 2006, 50, 2009-2015.
21. Leveque, D.; Nivoix, Y.; Jehl, F.; Herbrecht, R. Clinical pharmacokinetics of voriconazole. Int. J. Antimicrob. Agents 2006, 27, 274-294.
22. Theuretzbacher, U.; Ihle, F.; Derendorf, H. Pharmacokinetic/ pharmacodynamic profile of voriconazole. Clin. Pharmacokinet. 2006, 45, 649-663.
23. Rutar, T.; Cockerham, K. P. Periorbital zygomycosis (mucormycosis) treated with posaconazole. Am. J. Opthalmol. 2006, 142, 187-188.
24. van Burik, J. A.; Hare, R. S.; Solomon, H. F.; Corrado, M. L.; Kontoyiannis, D. P. Posaconazole is effective as salvage therapy in zygomycosis: A retrospective summary of 91 cases. Clin. Infect. Dis. 2006, 42, e61-e65.
25. Courtney, R.; Sansone, A.; Smith, W.; Marbury, T.; Statkevich, P.; Martinho, M.; Laughlin, M.; Swan, S. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J. Clin. Pharmacol. 2005, 45, 185-192.
26. Courtney, R.; Pai, S.; Laughlin, M.; Lim, J.; Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob. Agenty Chemother. 2003, 47, 2788-2795.
27. Sobue, S.; Tan, K.; Shaw, L.; Layton, G.; Hust R. Comparison of the pharmacokinetics of fosfluconazole and fluconazole after single intravenous administration of fosfluconazole in healthy Japanese and Caucasian volunteers. Eur. J. Clin. Pharmacol. 2004, 60, 247-253.
28. McCormack, P. I.; Perry, C. M. Caspofungin: A Review of Its Use in the Treatment of Fungal Infections. Drugs 2005, 65, 2049-2068.
29. Chandrasekar, P. H.; Manavathu, E. K. Caspofungin. Drugs Today 2002, 38, 829-846.
30. Kurtz, M. B.; Heath, I. B.; Marrinan, J.; Dreikom, S.; Onishi, J.; Douglas, C. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob. Agents Chemother. 1994, 38, 1480-1489.
31. Pfaller, M. A.; Diekema, D. J.; Messer, S. A.; Hollis, R. J.; Jones, R. N. In Vitro Activities of Caspofungin Compared with Those of Fluconazole and Itraconazole Against 3,959 Clinical Isolates of Candida spp., Including 157 Fluconazole-Resistant Isolates. Antimicrob. Agents Chemother. 2003, 47, 1068-1071.
32. Serrano, M. C.; Valverde-Conde A.; Chávez, M. M. In Vitro Activity of Voriconazole, Itraconazole, Caspofungin, Anidulafungin (VER002, LY303366) and Amphotericin B Against Aspergillus spp. Diagn. Microbiol. Infect Dis. 2003, 45, 131-135.
33. Cuenca-Estrella M. Combinations of antifungal agents in therapy-what value are they? J. Antimicrob. Chemother. 2004, 54, 854-869.
34. Stone, J. A.; Holland, S. D.; Wickersham, P. J.; Sterrett, A.; Schwartz, M.; Bonfiglio, C.; Hesney, M.; Winchell, G. A.; Deutsch, P. J.; Greenberg, H.; Hunt, T. L.; Waldman, S. A. Single-and Multiple-Dose Pharmacokinetics of Caspofungin in Healthy Men. Antimicrob. Agents Chemother. 2002, 46, 739-745.
35. Wals T. J.; Teppler, H.; Donowitz, G. R.; Maertens, J. A.; Baden, L. R.; Dmoszynska, A.; Cornely, O. A.; Bourque, M. R.; Lupinacci, R. J.; Sable, C. A.; DePauw, B. E. Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and Neutropenta. N. Eng. J. Med. 2004, 351, 1391-1402
36. Jarvis, B.; Figgitt, D. P.; Scott, L. J. Micafungin. Drugs 2004, 64, 969-982.
37. Denning, D. W. Echinocandin Antifungal Drugs. Lancet 2003, 362, 1142-1151.
38. Van Burik, J. H.; Ratanatharathom, V.; Stepan, D. E.; Miller, C. B.; Lipton, J. H.; Vesole, D. H.; Bunin, N.; Wall, D. A.; Hiemenz, J. W.; Satoi, Y.; Lee, J. M.; Walsh, T. J. Micafungin Versus Fluconazole for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Hemotopoietic Stem Cell Transplantation. Clin. Infect. Dis. 2004, 39, 1407-1416.
39. Ostrosky-Zeichner, I.; Rex, J. H.; Pappas, P. G.; Hamill, R. J.; Larsen, R. A.; Horowitz, H. W.; Powderly, W. G.; Hyslop, N.; Kauffman, C. A.; Cleary, J.; Mangino, J. E.; Lee, J. Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States. Antimicrob. Agents Chemother. 2003, 47, 3149- 154.
40. Krause, D. S.; Simjee, A. E.; Van Rensburg, C.; Viljoen, J.; Walsh, T. J.; Goldstein, B. P.; Wible, M.; Henkel, T. A Randomized, Double-Blind Trial of Anidulafungin Versus Fluconazole for the Treatment of Esophageal Candidiasis. Clin. Infect. Dis. 2004, 39, 770-775.
41. Krause, D. S.; Reinhardt, J.; Vazquez, J. A.; Reboli, A.; Goldstein, B. P.; Wible, M.; Henkel, T. Phase 2, Randomized, Dose-Ranging Study Evaluating the Safety and Efficacy of Anidulafungin in Invasive Candidiasis and Candidemia. Antimicrob. Agents Chemother. 2004, 48, 2021-2024.
42. Kobayashi, D.; Kondo, K.; Uehara, N.; Otokozawa, S.; Tsuji, N.; Yagihashi, A. and Watanabe, N. Endogenous Reactive Oxygen Species Is an Important Mediator of Miconazole Antifungal Effect Antimicrob. Agents Chemother. 2002 46, 3113-3117.
43. Francois, I. E. J. A.; Cammue, H. P. A.; Borgers, M.; Ausma, J.; Dispersyn, G. D.; Thevissen, K. Azoles: Mode of Antifungal Action and Resistance Development. Effect of Miconazole on Endogenous Reactive Oxygen Species production in Candida Albicans. Anti-Infective Agents Med. Chem. 2006, 5, 3-13.
44. Boyd, B. and Castaner, J. BAL-4815/BAL8557: Antifungal Agent. Drugs Future 2006, 31, 187-195.
45. Schmitt-Hoffmann, A.; Roos, B.; Heep, M.; Schleimer, M.; Weidekamm, E.; Brown, T.; Roehrle, M.; Beglinger, C. Single-Ascending-Dose Pharmacokinetics and Safety of the Novel Broad-Spectrum Antifungal Triazole BAL4815 After Intravenous Infusions (50, 100, and 200 Milligrams) and Oral Adminitrations (100, 200, and 400 Milligrams) of its Prodrug, BAL8557, in Healthy Volunteers. Antimicrob. Agents Chemother. 2006, 50, 279-285.
46. Schmitt-Hoffmann, A.; Roos, B.; Maares, J.; Heep, M.; Spickerman, J.; Weidekamm, E.; Brown, T.; Roehrle, M. Multiple-Dose Pharmacokinetics and Safety of the New Antifungal Triazole BAL4815 After Intravenous and Oral Administrations of its Prodrug, BAL8557, in Healthy Volunteers. Antimicrob. Agents Chemother, 2006, 50, 286-293.
47. Ramos, G.; Cuenca-Estrella, M.; Monzón, A.; Rodríguez-Tudela, J. L. In-Vitro Comparative Activity of UR-9825, Itraconazole, and Fluconazole Against Clinical Isolates of Candida spp. J. Antimicrob. Chemother. 1999, 44, 283-286.
48. Miller, J. L.; Schell, W. A.; Wills, E. A.; Toffaletti, D. L.; Boyce, M.; Benjamin Jr. D. K.; Bartroli, J.; Perfect, J. R. In Vitro and In Vivo Efficacies of the New Triazole Albaconazole Against Cryptococcus neoformans. Antmicrob. Agents Chemother. 2004, 48, 384-387.
49. Capilla, J.; Yustes, C.; Mayayo, E.; Fernández, B.; Ortoneda, M.; Pastor, F. J.; Guarro, J. Efficacy of Albaconazole (UR-9825) in Treatment of Disseminated Scedosorium prolificans Infection in Rabbits. Antimicrob. Agents Chemother. 2003, 47, 1948-1951.
50. Kamai, Y.; Kubota, M.; Fukuoka, T.; Kamai, Y.; Maeda, N.; Hosokawa, T.; Shibayama, T.; Uchida, K.; Yamaguchi, H.; Kuwahara, S. Efficacy of CS-758, a Novel Triazole, Against Experimental Fluconazole-Resistant Oropharyngeal Candidiasis in Mice. Antimicro. Agents Chemother. 2003, 47, 601-606.
51. Sorbera, L. A.; del Fresno, M.; Rabasseda, X. CS-758 Antifungal Lanosterol 14α-Demethylase Inhibitor. Drugs Future 2003, 28, 217-223.
52. Cuenca-Extrella, M.; Gómez-López, A.; Mellado, E.; García-Effrón, G.; Rodríguez-Tudela, J. L. In Viro Activities of Ravuconazole and Four Other Antifungal Agents Against Fluconazole-Resistant or -Susceptible Clinical Yeast Isolates. Antimicrob. Agents Chemother. 2004, 48, 3107-3111
53. Praller, M. A.;. Messer, S. A.; Hollis, R. J.; Jones, R. N. and the Sentry Participants Group. Antifungal Activities of Posaconazole, Ravuconazole, and Voriconazole Compared to Those of Itraconzole and Amphotericin B Against 239 Clinical Isolates of Aspergillus spp. ad Other Filamentous Fungi. Antimicrob. Agents Chemother. 2002, 46, 1032-1037.
54. Clemons, K. V.; Stevens, D. A. Efficacy of Ravuconazole in Treatment of Mucosal Candidosis in SCID Mice. Antimicrob. Agents Chemother. 2001, 45, 3433-3436.
55. Kirkpatrick, W. R.; Perea, S.; Coco, B. J.; Patterson, T. F. Efficacy of Ravuconazole (BMS-207147) in a Guinea Pig Model of Disseminated Aspergillosis. J. Antimicrob. Chemother. 2002, 49, 353-357.
56. Andes, D.; Marchillo, K.; Lowther, J.; Bryskier, A.; Stamstad, T.; Conklin, R. In Vivo Pharmacodynamics of HMR 3270, a Glucan Synthase inhibitor, in a Marine Candidiasis Model. Antimicrob. Agents Chemother. 2003, 47, 1187-1192.
57. Warn, P. A.; Sharp, A.; Morrissey, G.; Denning, D. W. Activity of Aminocandin (IP960) Compared With Amphotericin B and Fluconazole in a Neutropenic Murine Model of Disseminated Infection Caused by a Fluconazole-Resistant Strain of Candida Tropicalis. J. Antimicrob. Chemother. 2005, 56, 590-593.
58. Kasanah, N.; Hamann, M. T. SPK-843 Aparts/Kaken. Curr. Opin. Invest. Drugs 2005, 6, 845-853.
59. Kantarcioglu, A. S.; Yucel, A.; Vidotto, V. In Vitro Activity of a New Polyene SPK-843 Against Candida spp., Cryptococcus Neoformans and Aspergillus spp. Clinical Isolates. J. Chemother. 2003, 15, 296-598.
60. López, S.; Castello, M. V.; Zacchino, S. A.; Domínguez, J. N.; Lobo, G.; Charris-Charris, J.; Cortés, J. C. G.; Ribas, J. C.; Devia, C.; Rodriguez, A. M.; Enriz, R. D. In Vitro Antifungal Evaluation and Structure-Activity Relationships of a New Series of Chalcone Derivatives and Synthetic Analogues, With Inhibitory Properties Against Polymers of the Fungal Cell Wall. Bioorg. Med. Chem. 2001, 9, 1999-2013.
61. Vargas, L. Y.; Castelli, M. V.; Kouzaetsov, V. V.; Urbina, J. M.; López, S.; Sortino, M.; Enriz, R. D.; Ribas, J. C.; Zacchino, S. In Vitro Antifungal Activity of New Series of Homoallylamines and Related Compounds With Inhibitory Properties of the Synthesis of Fungal Cell Wall Polymers. Bioorg. Med. Chem. 2003, 11, 1531-1550.
62. López, S.; Castelli, M. V.; De Campos, F.; Correa, R.; Filho, V. C.; Yunes, R. A.; Zamora, M. A.; Enriz, R. D.; Ribas, J. C.; Furlan, R. L. E.; Zacchino, S. A. In Vitro Antifungal Properties, Structure-Activity Relationships and Studies on the Mode of Action of N-Phenyl, N-Aryl, N-Phenylalkyl Maleimides and Related Compounds. Arzneim.-Forsch. 2005, 55, 123-132.
63. Brayman, T. G.; Wilks, J. W. Sensitive Assay for Antifungal Activity of Glucan Synthase Inhibitors That Uses Germ Tube Formation in Candida albicans as an End Point. Antimicrob. Agents Chemother. 2003, 47, 3305-3310.
64. Karolyhazy, L.; Freile, M.; Anwair, M. N. S.; Beke, G.; Giannini, F.; Castelli, M. V.; Sortino, M.; Ribas, J. C.; Zacchino, S.; Matyus, P.; Enriz, R. D. Synthesis, In Vitro/In Vivo Antifungal Evaluation and Structure-Activity Relationship Study of 3(2H)-Pyridazinones. Arzneim.-Forsch, 2003, 53, 738-743.
65. Kondch, O.; Inagaki, Y.; Fukuda, H.; Mizuguchi, E.; Ohya, Y.; Arisawa, M.; Shimma, N.; Aoki, Y.; Sakaitani, M. and Watanabe, T. Piperazine Propanol Derivative as a Novel Antifungal Targeting 1,3-β-D-Glucan Synthase. Biol. Pharm. Bull 2005, 28, 2138-2141
66. Gossnitzer, E; Malli, R.; Schuster, S.; Favre, B.; Ryder, N. S. Novel High Energy Intermediate Analogs With Triazasterol-Related Structures as Inhibitors of Ergosterol Biosynthesis. Part I: Synthesis and Antifingal Activity of N-Alkyl-N'-(phenethyl- and Cyclohexenylethyl)guanidines and N2-Substituted 2-Imidazolinamines. Archiv der Pharmazie 2003 335, 535-546.
67. Gossnitzer, E.; Punkenhofer, A.; Ryder, N. S. Novel High Energy Intermediate Analogs With Triazasterol-Related Structures as Inhibitors of Ergosterol Biosynthesis. Part IV: Antimicrobial Activity of Mono-, Bi-, and Tricyclic 8,13,15-Triazasteroid Analogues Including the Synthesis of Novel 4-Alkylamino- and 4-Alkenylamino-9-hydroxypyrimidoisoquinolines. Archiv der Pharmazie 2003, 336, 336-344.
68. Quesnelle, C. A.; Gill. P,; Dodier, M.; St. Laurent, D.; Serrano-Wu, M.; Marinier, A.; Martel, A.; Mazzucco, C. E.; Stickle, T. M.; Barrett, J. F.; Vyas, D. M.; Balasubramanian, B. N. Sordaricin Antifungal Agents. Bioorg. Med. Chem. Lett. 2003, 13, 519-524.
69. Serrano-Wu, M. H.; St Laurent, D. R.; Carroll, T. M.; Dodier, M.; Gao, Q.; Gill, P.; Quesnelle, C.; Marinier, A.; Mazzucco, C. E.; Regueiro-Ren, A.; Stickle, T. M.; Wu, D.; Yang, H.; Yang, Z.; Zheng, M.; Zoeckler, M. E.; Vyas, D. M.; Balasubramanian, B. N. Identification of a Broad-Spectrum Azasordarin With Improved Pharmacokinetic Properties. Bioorg. Med. Chem. Lett. 2003, 13, 1419-1423.
70. Basilio, A.; Justice, M.; Harris, G.; Bills, G.; Collado, J.; de la Cruz, M.; Diez, M. T.; Hernández, P.; Liberator, P.; Nielsen Kahn, J.; Pelaez, F.; Platas, G.; Schmatz, D.; Shastry, M.; Tormo, J. R.; Andersen, G. R.; Vicente, F. The Discovery of Moriniafungin, a Novel Sordarin Derivative Produced by Morinia Pestalozzioides. Bioorg. Med. Chem. 2006, 14, 560-566.
71. Ryu, C. K.; Sun, Y. J.; Shim, J. Y.; You, H. J.; Choi, K. U.; Lee, H. Synthesis and Antifungal Activity of 6,7-Bis-S-(Aryl)thio]-5,8-Quinolinediones. Arch. Pharm. Res. 2002, 25, 795-800.
72. Cushion, M. T.; Walzer, P. D.; Collins, M. S.; Rebholz S.; Vanden Eynde, J. J.; Mayence, A.; Huang, T. L. Highly active anti- Pneumocystis carini compounds in a library of novel piperazine-linked bisbenzamidines and related compounds. Antimicrob. Agents Chemother 2004, 48, 4209-4216.
73. Cushion, M. T.; Walzer, P.D.; Ashbaugh, A.; Rebholz, S.; Brubaker, R.; Vanden Eynde, J. J.; Mayence, A.; Huang, T. L. In vitro selection end in vivo efficacy of piperazine- and alkanediamide-linked bisbenzamidines against Pneumocystis pneumonia in mice. Antimicrob. Agents Chemother. 2006, 50, 2337-2343